About Joao Pedro de Magalhaes, Ph.D.
Professor João Pedro de Magalhães graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium.
Following further training in genetics at Harvard Medical School (Boston, USA), in 2008 Prof de Magalhaes joined the University of Liverpool in the UK and established the Integrative Genomics of Ageing group (https://pcwww.liv.ac.uk/~aging/). His research on genetics, ageing and longevity has been widely featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.), and he has published over 100 scientific papers.
Prof de Magalhaes is a world-leader in big data and computational analyses, including genomics and machine learning, in ageing, longevity and age-related diseases. In addition, he has a long term interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent. Prof de Magalhaes has given over 100 invited talks in international conferences, including three TEDx talks, and in many academic institutions and companies (e.g., Google’s Calico and Allianz). He also makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). Prof de Magalhaes is an advisor/consultant for various organizations, including nonprofit foundations and charities, universities, investment funds and biotech companies.
He is Chief Scientific Officer of Centaura, an ambitious biotech company in Switzerland focused on healthy ageing (https://centaura.com/), and founded his own his company Magellan Science Ltd (http://magellan-science.com).
Related Organizations
Related News
May 13, 2022
Professor João Pedro de Magalhães leads the Genomics of Ageing and Rejuvenation Lab at the Institute of Inflammation and Ageing in the University of Birmingham. He is also CSO of YouthBio Therapeutics, a US-based biotech company that develops rejuvenation gene therapies based on partial reprogramming by Yamanaka factors. Last year, he co-authored The hoverfly and...
March 10, 2021
Dr. João Pedro de Magalhães is a Professor at the University of Liverpool, England, where he studies aging and longevity at the genetic level, and he is also an affiliate Principal Investigator in the Neuroendocrinology and Aging Group at the University of Coimbra, Portugal. Dr. de Magalhães has built the Human Ageing Genomic Resources (HAGR),...
February 24, 2021
A bold feature article published in Drug Discovery Today illustrates the coming of age of longevity pharmacology. Dr. João Pedro de Magalhães, one of the biggest names in longevity research, outlined some of the great strides taken in the last two decades, as various discoveries have been made in the biology of aging. Lifespan has...
June 03, 2020
On Tuesday, June 30, the Journal Club returns, and our special guest Dr. João Pedro de Magalhães will be giving a talk and taking questions about the CellAge database. Dr. João Pedro de Magalhães and his team at the University of Liverpool recently published a new study in which they used a systems biology approach...
